Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.
about
The role of the gut microbiota in the pathogenesis of antiphospholipid syndromeIdentification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome.Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome.Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome.The endothelium in atherogenesis.Induction and treatment of the antiphospholipid syndrome--lessons from animal models.Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary iAntiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice.Anti-β2-glycoprotein I paratopes and β2-glycoprotein I epitopes characterization using random peptide libraries.Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I.High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome.Cerebral haemostasis and antiphospholipid antibodies.Autoantibodies associated with reproductive failure.P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome.From rheumatic fever to Libman-Sacks endocarditis: is there any possible pathogenetic link?Infectious origin of the antiphospholipid syndrome.Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature.Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus.Molecular mimicry in systemic lupus erythematosus.Complement activation and pregnancy failure.Current knowledge regarding Asherson's syndrome.Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies.Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.Fulminant ecchymosis as the initial manifestation of antiphospholipid syndrome (APS) triggered by respiratory syncytial virus (RSV) infection: A case report and review of the literature.The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies.The future of autoimmunity.Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo.Probiotic supplementation with Lactobacillus casei (Actimel) induces a Th1 response in an animal model of antiphospholipid syndrome.Concomitant isolation of protein C inhibitor and unnicked beta2-glycoprotein I.Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?Systemic antiphospholipid syndrome.Oxidatively altered IgG with increased immunoreactivity to β2-glycoprotein I and its peptide clusters influence human coronary artery endothelial cells.Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of β(2) glycoprotein I.Anti-beta2-glycoprotein I ELISA: methodology, determination of cut-off values in 434 healthy Caucasians and evaluation of monoclonal antibodies as possible international standards.Induction of anti-β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes
P2860
Q26866133-E5F6636C-FFDC-43DC-ADD2-72AE3BEC646FQ30896030-38A54419-D77F-4FA4-834A-E487251D5B95Q33330858-78D5709F-A1E4-41C4-BADE-06E6F17D12E2Q33341518-51DE9EEB-295A-4001-AE6E-64BB5F201F32Q33915443-C781BEDA-7489-4510-8989-57DAD8BF5A28Q34319733-1D8DCE04-9C35-4325-843B-6D5E341ADD26Q34397548-B19ACE17-5003-4523-82E2-5DD9597EE769Q35070716-5FC7DD93-E32F-4CC4-9A62-4233AFA029E8Q35167094-32B3B9BB-E80B-43DA-B9C8-83B7B5024FDEQ35419865-5FE0A267-24C7-4A50-8EB5-C849BD2C7974Q35553532-5AF4929C-E3FD-4208-B776-B54B64B1F154Q35625236-15874D61-EC18-4F74-9C95-0F11E455E357Q35918355-E2F20138-64D6-45B0-BB26-D3986782D589Q36013889-EBC82A36-69B7-4A85-8E55-CC1FC406A3F4Q36283452-FA48BB7D-E733-43F5-8121-22B96C4AE2F4Q36339540-9EF6C9B4-8E7F-40EC-A151-95A47409B24CQ36951078-1A24C46D-7C27-4835-81E6-55D654424470Q37625571-F5AC8038-F68B-4B86-B371-2C37AD712AC3Q37625583-4E93851C-9667-43D2-9899-C06558339EABQ37638376-226C7469-F519-4CAC-8586-63BDA1192360Q37755290-FB9B8DC9-3906-4B93-8F6C-569CA93B655CQ37824302-94DF6B17-716C-499D-AC02-829ECCA51998Q38175886-1DD01E64-7B69-4121-A2D5-8B9F0AC0164AQ38297315-C24BE1E8-3B72-4A78-9171-27B8631D4F76Q39030234-884515DA-77E3-4D7A-BB37-F4869C7A4E7AQ40695735-4975779D-BAEB-4087-B7AB-6FBD3D491BE0Q41915133-8BD6480E-219F-429B-8E4A-1C4B520794F6Q43742774-A5BAAFAD-B927-400B-8668-DF4AC1B77775Q43786536-F4101871-3071-4AC1-9AF9-3CB09ACF01D5Q43882937-2DBC0782-0243-42D1-9E99-27343F598710Q46970279-85A793BF-17DB-4B7E-B6B3-218EA0BA07B2Q47829847-6C26FF00-9C00-4671-A410-9AA7082E03A3Q48035289-0A9B1454-7EC2-41E8-95FC-BD80BBACA763Q48238011-5D82020C-FB8A-4DDE-BBB8-B4769746671FQ50943891-5724D194-FD25-4C8C-A310-BE75627362BFQ51014103-0954B0E7-BB93-40F2-91DD-2ABB1D09FAF8Q53331016-8B80FB30-5118-40DD-AAFB-AF14B2875A19Q57983447-E57F7A1C-A392-43B3-99E2-C35B5DBF7006
P2860
Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Prevention of experimental ant ...... ivation by synthetic peptides.
@ast
Prevention of experimental ant ...... ivation by synthetic peptides.
@en
type
label
Prevention of experimental ant ...... ivation by synthetic peptides.
@ast
Prevention of experimental ant ...... ivation by synthetic peptides.
@en
prefLabel
Prevention of experimental ant ...... ivation by synthetic peptides.
@ast
Prevention of experimental ant ...... ivation by synthetic peptides.
@en
P2093
P2860
P356
P1476
Prevention of experimental ant ...... ivation by synthetic peptides.
@en
P2093
E Katchalski-Katzir
P2860
P304
P356
10.1073/PNAS.96.9.5164
P407
P577
1999-04-01T00:00:00Z